Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call Transcript
Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
Nuwellis, Inc. (NASDAQ:NUWE) Shares Shorted: Short Interest Up 339.6% in September
Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System
Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences
Nuwellis, Inc. (NASDAQ:NUWE) Sees Significant Decline in Short Interest
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer
Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy